CXCL5/ENA-78 Antibody (33103) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: WB
• Clone: 33103
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

CXCL5/ENA-78 Antibody (33103) [Alexa Fluor® 350] Summary

• Immunogen: E. coli-derived recombinant human CXCL5/ENA-78
  Ala37-Asn114
  Accession # P42830
• Specificity: Detects human CXCL5/ENA‑78 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human CXCL1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 16, recombinant mouse CXCL1, 2, 4, 6, 7, 9, 10, 11, 12, 15, 16, recombinant rat CXCL5,
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL5/ENA-78 Antibody (33103) [Alexa Fluor® 350]

• chemokine (C-C motif) ligand 5
• C-X-C motif chemokine 5
• CXCL5
• CXCL5/ENA-78
• ENA78
• ENA-78
• ENA-78(1-78)
• Epithelial-derived neutrophil-activating protein 78
• Neutrophil-activating peptide ENA-78
• neutrophil-activating protein 78
• SCYB5ENA78

Background

CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR-CXC chemokines which are angiostatic (1‑3). Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR⁺ chemokines, it shares 77% aa sequence identity with CXCL6/GCP-2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP-2, and CXCL8/IL-8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis (3‑6). Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers (6‑9). Full length CXCL5 (78 aa) is trimmed at the N-terminus by cathepsin G and chymotrypsin to ENA-74 (74 aa) and ENA-70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5 (10, 11). CXCL5 exerts its effects primarily through interactions with CXCR2 (6, 12). It also binds duffy antigen receptor for chemokines (DARC), which can limit CXCR2-mediated responses (13, 14).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.